期刊： CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2021; 19 (3)
Parkinson's disease is often complicated by psychiatric symptoms. Psychiatrists are caught in a dilemma between such symptoms and physical treatment s......
期刊： CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2021; 19 (3)
Objective: The purpose of this study is to investigate the safety, tolerability and efficacy of titrating dose of rivastigmine oral solution in patien......
期刊： CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2021; 19 (2)
Repetitive transcranial magnetic stimulation (rTMS) and intermittent theta-burst stimulation (iTBS) are evidenced-based treatments for patients with m......
期刊： CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2021; 19 (3)
Early detection and prevention of Alzheimer's disease (AD) is important. The current treatment for early AD is acetylcholine esterase inhibitors (AChE......
期刊： CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2021; 19 (1)
Objective: Melatonin has been considered to have an essential role in the pathophysiology of Alzheimer's disease (AD) for its regulatory function on c......
期刊： CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2020; 18 (1)
Objective: This study was performed to evaluate the efficacy of metformin on liver fat content (LFC) in first episode schizophrenia patients with olan......
期刊： CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2020; 18 (2)
Objective: We conducted a meta-analysis of randomized controlled trials to explore whether vitamin D supplementation is beneficial for symptom improve......
期刊： CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2020; 18 (1)
Objective: Valproic acid (VPA) is an anticonvulsant and commonly long term used as a mood stabilizer for patients with mood disorders. However its chr......
期刊： CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2020; 18 (1)
Objective: Patients with opioid use disorder (OUD) have impaired attention, inhibition control, and memory function. The aldehyde dehydrogenase 2 (ALD......
期刊： CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2020; 18 (1)
Objective: Therapeutic drug monitoring helps clinicians in choosing the right drug and adjust its dose in specific patients. To this end, we aimed to ......
期刊： CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2020; 18 (3)
Objective: There are very few studies on the effectiveness of stimulant medications for the treatment of disruptive mood and behavior problems in youn......
期刊： CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2020; 18 (4)
Omega-3 polyunsaturated fatty acids (or omega-3 PUFAs, n-3 PUFAs) are essential nutrients throughout the life span. Recent studies have shown the impo......
期刊： CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2020; 18 (4)
Psychiatric symptoms are common after traumatic brain injury (TBI), and some patients have poor drug therapeutic efficacy. We report a successfully tr......
期刊： CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2019; 17 (2)
Objective: Patients with chronic neuropathic pain (CNP) have a higher incidence to develop depression. However, its pathogenesis has not yet been full......
